Typhoid Vaccine Acceleration Consortium Malawi: A Phase III, Randomized, Double-blind, Controlled Trial of the Clinical Efficacy of Typhoid Conjugate Vaccine Among Children in Blantyre, Malawi

James E Meiring, Matthew B Laurens, Pratiksha Patel, Priyanka Patel, Theresa Misiri, Kenneth Simiyu, Felistas Mwakiseghile, J Kathleen Tracy, Clemens Masesa, Yuanyuan Liang, Marc Henrion, Elizabeth Rotrosen, Markus Gmeiner, Robert Heyderman, Karen Kotloff, Melita A Gordon, Kathleen M Neuzil, James E Meiring, Matthew B Laurens, Pratiksha Patel, Priyanka Patel, Theresa Misiri, Kenneth Simiyu, Felistas Mwakiseghile, J Kathleen Tracy, Clemens Masesa, Yuanyuan Liang, Marc Henrion, Elizabeth Rotrosen, Markus Gmeiner, Robert Heyderman, Karen Kotloff, Melita A Gordon, Kathleen M Neuzil

Abstract

Background: Typhoid fever is an acute infection characterized by prolonged fever following the ingestion and subsequent invasion of Salmonella enterica serovar Typhi (S. Typhi), a human-restricted pathogen. The incidence of typhoid fever has been most reported in children 5-15 years of age, but is increasingly recognized in children younger than 5 years old. There has been a recent expansion of multidrug-resistant typhoid fever globally. Prior typhoid vaccines were not suitable for use in the youngest children in countries with a high burden of disease. This study aims to determine the efficacy of a typhoid conjugate vaccine (TCV) that was recently prequalified by the World Health Organization, by testing it in children 9 months through 12 years of age in Blantyre, Malawi.

Methods: In this Phase III, individually randomized, controlled, double-blind trial of the clinical efficacy of TCV, 28 000 children 9 months through 12 years of age will be enrolled and randomized in a 1:1 ratio to receive either Vi-TCV or a meningococcal serogroup A conjugate vaccine. A subset of 600 of these children will be further enrolled in an immunogenicity and reactogenicity sub-study to evaluate the safety profile and immune response elicited by Vi-TCV. Recruiting began in February 2018.

Results: All children will be under passive surveillance for at least 2 years to determine the primary outcome, which is blood culture-confirmed S. Typhi illness. Children enrolled in the immunogenicity and reactogenicity sub-study will have blood drawn before vaccination and at 2 timepoints after vaccination to measure their immune response to vaccination. They will also be followed actively for adverse events and serious adverse events.

Conclusions: The introduction of a single-dose, efficacious typhoid vaccine into countries with high burden of disease or significant antimicrobial resistance could have a dramatic impact, protecting children from infection and reducing antimicrobial usage and associated health inequity in the world's poorest places. This trial, the first of a TCV in Africa, seeks to demonstrate the impact and programmatic use of TCVs within an endemic setting.

Clinical trials registration: NCT03299426.

Keywords: Africa; Malawi; TyVAC; children/pediatric; typhoid conjugate vaccine.

© The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America.

Figures

Figure 1.
Figure 1.
Passive surveillance enrollment flow. Abbreviations: SAE, serious adverse event; VE, vaccine efficacy.

References

    1. Dougan G, Baker S. Salmonella enterica serovar Typhi and the pathogenesis of typhoid fever. Annu Rev Microbiol 2014; 68:317–36.
    1. Crump JA, Mintz ED. Global trends in typhoid and paratyphoid Fever. Clin Infect Dis 2010; 50:241–6.
    1. Buckle GC, Walker CL, Black RE. Typhoid fever and paratyphoid fever: Systematic review to estimate global morbidity and mortality for 2010. J Glob Health 2012; 2:010401.
    1. Mogasale V, Maskery B, Ochiai RL, et al. . Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment. Lancet Glob Health 2014; 2:e570–80.
    1. Antillón M, Warren JL, Crawford FW, et al. . The burden of typhoid fever in low- and middle-income countries: a meta-regression approach. PLOS Negl Trop Dis 2017; 11:e0005376.
    1. Crump JA, Luby SP, Mintz ED.. The global burden of typhoid fever. Bull World Health Organ 2004; 82:346–53.
    1. World Health Organization. Typhoid vaccines position paper. Wkly Epidemiol Rec; 2008; 83:49–59.
    1. Lee JS, Mogasale VV, Mogasale V, Lee K. Geographical distribution of typhoid risk factors in low and middle income countries. BMC Infect Dis 2016; 16:732.
    1. Gunn JS, Marshall JM, Baker S, Dongol S, Charles RC, Ryan ET. Salmonella chronic carriage: epidemiology, diagnosis, and gallbladder persistence. Trends Microbiol 2014; 22:648–55.
    1. Marks F, von Kalckreuth V, Aaby P, et al. . Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health 2017; 5:e310–23.
    1. Kim JH, Mogasale V, Im J, Ramani E, Marks F. Updated estimates of typhoid fever burden in sub-Saharan Africa. Lancet Glob Health 2017; 5:e969.
    1. Warne T, Blum LS, Hyde T, et al. . Formative investigation of acceptability of typhoid vaccine during a typhoid fever outbreak in Neno District, Malawi. Am J Trop Med Hyg 2014; 91:729–37.
    1. Kabwama SN, Bulage L, Nsubuga F, et al. . A large and persistent outbreak of typhoid fever caused by consuming contaminated water and street-vended beverages: Kampala, Uganda, January - June 2015. BMC Public Health 2017; 17:23.
    1. Polonsky JA, Martínez-Pino I, Nackers F, et al. . Descriptive epidemiology of typhoid fever during an epidemic in Harare, Zimbabwe, 2012. PLOS One 2014; 9:e114702.
    1. Hendriksen RS, Leekitcharoenphon P, Lukjancenko O, et al. . Genomic signature of multidrug-resistant Salmonella enterica serovar Typhi isolates related to a massive outbreak in Zambia between 2010 and 2012. J Clin Microbiol 2015; 53:262–72.
    1. Muyembe-Tamfum JJ, Veyi J, Kaswa M, Lunguya O, Verhaegen J, Boelaert M. An outbreak of peritonitis caused by multidrug-resistant Salmonella Typhi in Kinshasa, Democratic Republic of Congo. Travel Med Infect Dis 2009; 7:40–3.
    1. Musicha P, Cornick JE, Bar-Zeev N, et al. . Trends in antimicrobial resistance in bloodstream infection isolates at a large urban hospital in Malawi (1998-2016): a surveillance study. Lancet Infect Dis 2017; 17:1042–52.
    1. Feasey NA, Masesa C, Jassi C, Faragher EB, Mallewa J, Mallewa M, et al. . Three epidemics of invasive multidrug-resistant Salmonella bloodstream infection in Blantyre, Malawi, 1998–2014. Clin Infect Dis 2015; 61(Suppl 4):S363–71.
    1. Feasey NA, Gaskell K, Wong V, et al. . Rapid emergence of multidrug resistant, H58-lineage Salmonella Typhi in Blantyre, Malawi. PLOS Negl Trop Dis 2015; 9.
    1. Wong VK, Holt KE, Okoro C, et al. . Molecular surveillance identifies multiple transmissions of typhoid in West Africa. PLOS Negl Trop Dis 2016; 10:e0004781.
    1. Pitzer VE, Feasey NA, Msefula C, et al. . Mathematical modeling to assess the drivers of the recent emergence of typhoid fever in Blantyre, Malawi. Clin Infect Dis 2015; 61(Suppl 4):S251–8.
    1. Darton TC, Meiring JE, Tonks S, et al. ; STRATAA Study Consortium. The STRATAA study protocol: a programme to assess the burden of enteric fever in Bangladesh, Malawi and Nepal using prospective population census, passive surveillance, serological studies and healthcare utilisation surveys. BMJ Open 2017; 7:e016283.
    1. Lin FY, Ho VA, Khiem HB, et al. . The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263–9.
    1. Mohan VK, Varanasi V, Singh A, et al. . Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study. Clin Infect Dis 2015; 61:393–402.
    1. Jin C, Gibani MM, Moore M, et al. . Efficacy and immunogenicity of a Vi-tetanus toxoid conjugate vaccine in the prevention of typhoid fever using a controlled human infection model of Salmonella Typhi: a randomised controlled, phase 2b trial. Lancet 2017; 390:2472–80.
    1. Lin FY, Ho VA, Khiem HB, et al. . The efficacy of a Salmonella Typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344:1263–9.
    1. World Health Organization. SAGE meeting of October 2017. Available at: Accessed 21 January 2018.
    1. Gavi TVA. Millions of children set to be protected against typhoid fever - Gavi, the Vaccine Alliance Available at: Accessed 19 April 2018.
    1. World Health Organization. Typhoid vaccines position paper Available at: Accessed 18 April 2018.
    1. Meiring JE, Patel P, Patel P, Gordon MA. Typhoid conjugate vaccines: making vaccine history in Africa, Expert Rev Vaccines. 2018;17:8,673–76.
    1. R Foundation for Statistical Computing. R: a language and environment for statistical computing. Available at: . Accessed 9 Auguat 2018.
    1. Greg Snow M. Package “blockrand” type package title randomization for block random clinical trials. Available at: Accessed 9 August 2018.
    1. Antillón M, Bilcke J, Paltiel AD, Pitzer VE. Cost-effectiveness analysis of typhoid conjugate vaccines in five endemic low- and middle-income settings. Vaccine 2017; 35:3506–14.
    1. Nyirenda LJ, Sandberg KI, Justice J. When are health systems ready for new vaccines? The introduction of pneumococcal vaccine in Malawi. Forum Dev Stud 2014; 41:317–36.
    1. Milligan R, Paul M, Richardson M, Neuberger A. Vaccines for preventing typhoid fever. Cochrane Database of Systematic Reviews 2018. Art. No.: CD001261
    1. Klemm EJ, Shakoor S, Page AJ, et al. . Emergence of an extensively drug-resistant Salmonella enterica serovar Typhi clone harboring a promiscuous plasmid encoding resistance to fluoroquinolones and third-generation cephalosporins. MBio 2018; 9:e00105–18.

Source: PubMed

Спонсоры и соавторы

Заболевания

Медикаментозные вмешательства

Подписаться